Per StockStory, this is a nice summary of the take-aways, from CEO Rob Davis's remarks on the Q2 2025 earnings conference call. [To be certain, the company is a cash flow and earnings. . . juggernaut -- now and always, over the last decade and a half, minimum.]
Do go read it all, as it contains the most salient questions and answers from the call as well:
. . .In the coming quarters, StockStory analysts will monitor (1) the pace of WINREVAIR’s adoption in new markets and additional indications, (2) progress on Merck’s multiyear cost optimization and reinvestment program, and (3) regulatory milestones for late-stage pipeline assets such as enlicitide, ENFLONSIA, and upcoming oncology approvals.
The trajectory of GARDASIL sales outside China and ongoing business development activity will also be key indicators of Merck’s execution and future growth potential. . . .
Now you know. Onward, to another hot, humid and hazy (Canadian wild-fires fed) dog days of Summer afternoon here. Smile. Be excellent to one another. Out.
नमस्ते
No comments:
Post a Comment